Pricing Models & Strategies to Make CAR-T Therapy AffordablePublished: May 14, 2018
Latest Advances in CAR-T Cell Manufacture & Clinical Developments
Dr Dan Ollendorf has been the Chief Scientific Officer for the Institute of Clinical and Economic Review (ICER) since 2007. In this role, he is responsible for the conduct of systematic reviews of the comparative effectiveness of high impact health care technologies, integration of decision analysis and budgetary impact modeling into reviews of clinical evidence, engagement and collaboration with multiple stakeholders, and coordination as well as scientific oversight of the broader health technology assessment process. His 30 years of health care experience include work in the hospital, informatics, insurance, managed care, and consulting sectors. Dan holds a PhD in clinical epidemiology from the University of Amsterdam, a Masters in Public Health from Boston University, and a Bachelor of Arts from the University of Rochester. He has authored over 60 peer-reviewed articles in major journals, and was on the Editorial Board of the Journal of Managed Care Pharmacy from 2009-2012. Dan currently serves on the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC), the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) HTA Council Working Group, and the Policy Forum of Health Technology Assessment International (HTAi).DOI: 10.18609/cgti.2018.033
Citation: Cell Gene Therapy Insights 2018; 4(4), 363-368.